BACKGROUND: Human leukocyte antigen-G (HLA-G) has been closely associated with diagnosis and prognosis in many types of human cancer. The current study aims to investigate soluble (s) HLA-G expression in patients with breast malignancy. PATIENTS AND METHODS: sHLA-G plasma expression was determined in 120 patients with breast cancer and 40 healthy controls using enzyme-linked immunosorbent assay. RESULTS: Plasma sHLA-G levels were significantly higher in breast cancer patients compared to healthy controls (p<0.001), with an area under the receiver operating characteristic (ROC) curve of 0.735 (95% Confidence interval=0.630-0.841, p<0.001). Significantly increased sHLA-G expression was detected in patients with mixed type of coexisting ductal and lobular breast lesions, compared to patients with pure ductal carcinoma or pure lobular neoplasia (p<0.05). CONCLUSION: sHLA-G expression is closely associated with the histological type of breast cancer. Our findings support the application of sHLA-G as a potential biomarker in body fluids for preoperative breast cancer detection and diagnosis.
BACKGROUND:Human leukocyte antigen-G (HLA-G) has been closely associated with diagnosis and prognosis in many types of humancancer. The current study aims to investigate soluble (s) HLA-G expression in patients with breast malignancy. PATIENTS AND METHODS: sHLA-G plasma expression was determined in 120 patients with breast cancer and 40 healthy controls using enzyme-linked immunosorbent assay. RESULTS: Plasma sHLA-G levels were significantly higher in breast cancerpatients compared to healthy controls (p<0.001), with an area under the receiver operating characteristic (ROC) curve of 0.735 (95% Confidence interval=0.630-0.841, p<0.001). Significantly increased sHLA-G expression was detected in patients with mixed type of coexisting ductal and lobular breast lesions, compared to patients with pure ductal carcinoma or pure lobular neoplasia (p<0.05). CONCLUSION: sHLA-G expression is closely associated with the histological type of breast cancer. Our findings support the application of sHLA-G as a potential biomarker in body fluids for preoperative breast cancer detection and diagnosis.
Authors: Fabrício C Dias; Erick C Castelli; Cristhianna V A Collares; Philippe Moreau; Eduardo A Donadi Journal: Front Immunol Date: 2015-02-02 Impact factor: 7.561
Authors: Anna Gillio-Tos; Maria da Graça Bicalho; Valentina Fiano; Chiara Grasso; Valentina Tarallo; Laura De Marco; Morena Trevisan; Marinabarbaradesousa Xavier; Renata Slowik; Newton S Carvalho; Carlos A Maestri; Hadriano M Lacerda; Daniela Zugna; Lorenzo Richiardi; Franco Merletti Journal: BMC Cancer Date: 2012-12-24 Impact factor: 4.430